

ARTICLE

Received 23 Mar 2015 | Accepted 6 Jul 2015 | Published 20 Aug 2015

DOI: 10.1038/ncomms9013

OPEN

# Structural mechanism for signal transduction in RXR nuclear receptor heterodimers

Douglas J. Kojetin<sup>1</sup>, Edna Matta-Camacho<sup>1</sup>, Travis S. Hughes<sup>1</sup>, Sathish Srinivasan<sup>2</sup>, Jerome C. Nwachukwu<sup>2</sup>, Valerie Cavett<sup>2</sup>, Jason Nowak<sup>2</sup>, Michael J. Chalmers<sup>1</sup>, David P. Marciano<sup>1</sup>, Theodore M. Kamenecka<sup>1</sup>, Andrew I. Shulman<sup>3,†</sup>, Mark Rance<sup>4</sup>, Patrick R. Griffin<sup>1</sup>, John B. Bruning<sup>5</sup> & Kendall W. Nettles<sup>2</sup>

A subset of nuclear receptors (NRs) function as obligate heterodimers with retinoid X receptor (RXR), allowing integration of ligand-dependent signals across the dimer interface via an unknown structural mechanism. Using nuclear magnetic resonance (NMR) spectroscopy, x-ray crystallography and hydrogen/deuterium exchange (HDX) mass spectrometry, here we show an allosteric mechanism through which RXR co-operates with a permissive dimer partner, peroxisome proliferator-activated receptor (PPAR)- $\gamma$ , while rendered generally unresponsive by a non-permissive dimer partner, thyroid hormone (TR) receptor. Amino acid residues that mediate this allosteric mechanism comprise an evolutionarily conserved network discovered by statistical coupling analysis (SCA). This SCA network acts as a signalling rheostat to integrate signals between dimer partners, ligands and coregulator-binding sites, thereby affecting signal transmission in RXR heterodimers. These findings define rules guiding how NRs integrate two ligand-dependent signalling pathways into RXR heterodimer-specific responses.

<sup>1</sup>Department of Molecular Therapeutics, The Scripps Research Institute-Scripps Florida, 130 Scripps Way, Jupiter, Florida 33458, USA. <sup>2</sup>Department of Cancer Biology, The Scripps Research Institute-Scripps Florida, 130 Scripps Way, Jupiter, Florida 33458, USA. <sup>3</sup>Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. <sup>4</sup>Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati, Cincinnati, Ohio 45267, USA. <sup>5</sup>School of Biological Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia. † Present address: Division of Pediatric Rheumatology, Children's Hospital of Orange County, Department of Pediatrics, University of California Irvine, Irvine, California 92697, USA. Correspondence and requests for materials should be addressed to D.J.K. (email: dkojetin@scripps.edu) or to K.W.N. (email: knettles@scripps.edu).

The nuclear receptor (NR) superfamily of transcription factors are broadly implicated in metazoan physiology, and modulate gene expression in response to steroids, lipids, bile acids and other small lipophilic molecules or synthetic ligands<sup>1</sup>. NRs harbour a C-terminal ligand-binding and transactivation domain (LBD), a central DNA-binding domain and a variable N-terminal disordered transactivation domain. These receptors transduce signals from ligand binding in the LBD to regulate gene expression by recruiting co-regulator proteins that modify chromatin and the associated transcriptional complex<sup>2</sup>.

The physical mechanisms governing allosteric signalling between NR ligands and coregulator-binding sites remain poorly understood. Allosteric control of NR function is modulated by a number of factors, including cell type-specific co-regulators<sup>3</sup>, post-translational modifications<sup>4,5</sup>, DNA recognition elements<sup>6–8</sup> and NR heterodimer partners<sup>9–11</sup>. Understanding the complex allosteric signalling of NRs requires first dissecting the signalling mechanisms within individual domains and binding sites, which will facilitate understanding the more difficult questions related to inter-domain communication<sup>12</sup>. Structural studies have revealed mechanisms that direct communication between ligand and coregulator-binding sites within a single LBD<sup>13,14</sup>. The fully active LBD conformer is well-characterized<sup>15–17</sup> and its conformation is conserved within the context of the full-length receptor<sup>18</sup>. In its agonist-stabilized conformation, the C-terminal helix, helix 12 forms one side, while helices 3–5 form the other sides of a co-regulator-binding site called the Activation Function-2 (AF-2) surface. Some NR antagonists, such as tamoxifen or RU486, contain a pendent side group that physically relocates helix 12 out of the active conformation thus blocking co-activator recruitment<sup>15,19,20</sup>. More recently, we identified a fine-tuning mechanism for indirectly modulating helix 12 conformation, allowing NRs to direct a graded range of signalling outputs from partial to full agonist<sup>21–24</sup>. We have also defined a structural mechanism whereby graded agonists and non-agonists do not fully stabilize the conformational dynamics of the AF-2 surface<sup>4,25–27</sup>. However, it is poorly understood how ligand binding to one LBD controls co-regulator recruitment to its dimer partner within a NR heterodimer complex.

A subset of NRs functions as heterodimers with retinoid X receptor (RXR), and thus provides a mechanism to integrate two distinct ligand signalling pathways<sup>28</sup>. In some contexts, RXR heterodimers can act as two independent signalling moieties<sup>29</sup>. However, allosteric phenomena between RXR and partner are not well-understood. First, some heterodimer partners, such as the peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ), farnesoid X receptor and liver X receptor (LXR), are ‘permissive’ for RXR activity, where the heterodimer is strongly activated by ligands for either partner in the dimer<sup>30,31</sup>. However, the integration of signals varies with both receptor and ligand combinations, which can produce either additive or synergistic effects<sup>32,33</sup>. Second, RXR heterodimers that contain retinoic acid receptor (RAR), vitamin D receptor (VDR) or thyroid hormone receptor (TR), are ‘non-permissive’ for RXR as they generally do not respond to RXR ligands<sup>34</sup>, or do so only in certain contexts in the presence of the partner ligand<sup>35,36</sup>. The structural mechanisms that generate this spectrum of signalling outcomes are unknown.

Here we present comprehensive structural analyses of a ‘permissive’ (PPAR $\gamma$ /RXR $\alpha$ ) and ‘non-permissive’ (TR/RXR) heterodimeric complex, which defines how a non-permissive dimer partner allosterically silences RXR. Solution nuclear magnetic resonance (NMR) spectroscopy reveals a mechanism by which the liganded state of TR, but not PPAR $\gamma$ , uniquely affects the conformational dynamics of RXR. A crystal structure


of the TR/RXR heterodimer defines a structural mechanism for this silencing, which occurs through a sequence of conformational relays between the helix 11 pairs that constitute most of the dimer interface, transferred to a rotation of helix 5 in the core of the RXR LBD, leading to disruption of the adjacent co-regulator- and ligand-binding sites. This allosteric signalling pathway is further confirmed by NMR and hydrogen/deuterium exchange (HDX) mass spectrometry. Notably, analysis of other NR dimers reveals that these structural changes are part of an evolutionarily conserved energetic network, defined by a statistical coupling analysis (SCA) method<sup>10</sup>, where helix 5 functions more generally as a signalling rheostat that integrates signals with the dimer interface, ligand and coregulator-binding sites.

## Results

**Conformational dynamics control RXR permissiveness.** The RXR agonist, 9-*cis*-retinoic acid (9cRA), stimulates transactivation of PPAR $\gamma$ /RXR $\alpha$  (Fig. 1a), verifying PPAR $\gamma$  as a permissive RXR $\alpha$  partner. However, 9cRA and another RXR agonist, LG100268 (LG268), have no effect on TR $\beta$ /RXR $\alpha$  (Fig. 1b) and VDR/RXR $\alpha$  (Supplementary Fig. 1), establishing TR $\beta$  and VDR as non-permissive RXR partners. To gain insight into the structural basis for this heterodimer-specific signalling, we performed solution NMR on isotopically labelled RXR $\alpha$  LBD alone as a homodimer, and in complex with unlabelled PPAR $\gamma$  LBD or TR $\beta$  LBD as heterodimers. This analysis enabled us to specifically observe conformational effects in RXR $\alpha$  that result from ligand binding to its heterodimer partner.

NMR resonances corresponding to residues within the apo-RXR $\alpha$  ligand-binding pocket and AF-2 surface are missing or have broad linewidths. These regions exist as a dynamic ensemble of conformations, exchanging between two or more conformations in a molten globule-like state on the  $\mu$ s–ms timescale<sup>37–39</sup>. Binding of 9cRA to the RXR $\alpha$  homodimer stabilizes the ligand-binding pocket and AF-2 surface<sup>37</sup> (Fig. 1b,c), resulting in the appearance and sharpening of NMR resonances relative to apo-RXR $\alpha$ . Thus, the NMR-observed structural mechanism by which an agonist activates RXR $\alpha$  occurs by stabilizing an active conformation. That is, agonist binding quenches the  $\mu$ s–ms conformational dynamics of the apo-RXR $\alpha$  ligand-binding pocket and surrounding regions, including the AF-2 surface. This mechanism is also supported by HDX mass spectrometry studies, which demonstrate stabilization of the RXR $\alpha$  ligand-binding pocket and AF-2 surface on ligand binding<sup>40–42</sup>. This conformational activation phenotype, whereby the dynamics of the apo-NR LBD is affected (stabilized) by agonist binding, has been observed for PPAR $\gamma$ <sup>25,26,39</sup>, VDR<sup>43,44</sup>, constitutive androstane receptor<sup>45</sup> and other receptors, indicating this may be a general feature for ligand activation of NRs.

To determine the mechanism through which PPAR $\gamma$  acts as a permissive dimer partner, we performed differential NMR analysis by adding unlabelled apo-PPAR $\gamma$  to 9cRA-bound isotopically labelled RXR $\alpha$ , with and without addition of the full PPAR $\gamma$  agonist, rosiglitazone (Fig. 1b,d). NMR chemical shift changes in RXR $\alpha$  are observed on addition of apo-PPAR $\gamma$  to the 9cRA-bound RXR $\alpha$ , consistent with complete formation of a heterodimer complex. Addition of rosiglitazone causes subtle but significant NMR chemical shift changes in RXR $\alpha$  (for example, S355 and G429 in the dimer interface) and only minor changes in NMR resonance linewidths for select residues. Thus, although heterodimerization with and ligand binding to PPAR $\gamma$  perturbs the conformation of RXR $\alpha$ , neither of these events dramatically affects the  $\mu$ s–ms dynamics of RXR $\alpha$ . This is in contrast to what occurs with the non-permissive RXR partner, TR $\beta$ , as detailed below.



**Figure 1 | NMR reveals a role for conformational dynamics in RXR permissiveness.** (a) CV-1 cells co-transfected with PPAR $\gamma$  expression plasmid, RXR $\alpha$  expression plasmid and a PPAR-responsive luciferase reporter. Cells were treated with vehicle, 10  $\mu\text{M}$  9cRA and/or 10  $\mu\text{M}$  rosiglitazone for 24 h. Magenta and black bars are coloured to match NMR data in **d**, where ligand content is the same. Luciferase activity is shown normalized to vehicle-treated cells and was performed in quadruplicate, plotted with the average ( $\pm$  s.e.m) and representative of at least three experiments. (b) CV-1 cells co-transfected with TR $\beta$  expression plasmid, RXR $\alpha$  expression plasmid and a TR-responsive luciferase reporter. Cells were treated with vehicle, 100 nM LG100268 (LG268) and/or 1  $\mu\text{M}$  T3 for 24 h. Luciferase activity is shown normalized to vehicle-treated cells and was performed in quadruplicate, plotted with the average ( $\pm$  s.e.m) and representative of at least two experiments. Magenta and black bars are coloured to match NMR data in **e**, where ligand content is the same. (c) Structural location of RXR residues mentioned in the NMR analysis. (d) Overlay of 2D [ $^1\text{H}$ , $^{15}\text{N}$ ]-TROSY-HSQC NMR data for [ $^2\text{H}$ , $^{13}\text{C}$ , $^{15}\text{N}$ ]-RXR $\alpha$  LBD in the apo form and coloured magenta—with the same bound to 9cRA and coloured black. (e) Overlay of 2D [ $^1\text{H}$ , $^{15}\text{N}$ ]-TROSY-HSQC NMR data for [ $^2\text{H}$ , $^{13}\text{C}$ , $^{15}\text{N}$ ]-RXR $\alpha$  LBD bound to 9cRA and heterodimerized to apo-PPAR $\gamma$  and coloured magenta—with the same bound to rosiglitazone (Rosi) and coloured black. (f) Overlay of 2D [ $^1\text{H}$ , $^{15}\text{N}$ ]-TROSY-HSQC NMR data for [ $^2\text{H}$ , $^{13}\text{C}$ , $^{15}\text{N}$ ]-RXR $\alpha$  LBD bound to 9cRA and heterodimerized to apo-TR $\beta$  and coloured magenta—with the same bound to T3 and coloured black.

To determine the mechanism through which TR $\beta$  acts as a non-permissive RXR heterodimer partner, we performed differential NMR analysis by adding unlabelled apo-TR $\beta$  to 9cRA-bound isotopically labelled RXR $\alpha$ , with and without addition of the TR $\beta$  agonist, T3 (Fig. 1b,e). In contrast to PPAR $\gamma$ , addition of apo-TR $\beta$  exerts a profound effect on the  $\mu\text{s}$ –ms conformational dynamics of 9cRA-bound RXR $\alpha$ , where a large number of agonist-bound RXR $\alpha$  NMR resonances revert to an apo-like NMR profile. NMR resonances that are destabilized—missing or have broad linewidths indicating increased  $\mu\text{s}$ –ms motion—correspond to RXR $\alpha$  residues in the ligand-binding pocket (for example, I324, G323, T328, G329, G341, G343 and S355), helix 11 (for example, G413 and G429) and other nearby regions such as helix 8 (for example, G368). Even more striking is that the addition of the TR $\beta$  agonist, T3, re-stabilizes these agonist-bound RXR $\alpha$  residues by decreasing motion on the  $\mu\text{s}$ –ms timescale, resulting in a reappearance of

NMR resonances for these regions. Notably, many of the missing NMR resonances in the apo-TR $\beta$ /agonist-RXR $\alpha$  heterodimer correspond to residues in the apo-RXR $\alpha$  homodimer that are stabilized on binding 9cRA. Our NMR studies indicate that these residues are not affected by PPAR $\gamma$  heterodimerization or ligand binding to PPAR $\gamma$ , but they are significantly affected by TR $\beta$  heterodimerization and ligand binding to TR $\beta$ . In total, these data indicate that the mechanism through which RXR $\alpha$  is allosterically silenced by TR $\beta$  but not PPAR $\gamma$ , involves conformational dynamics on the  $\mu\text{s}$ –ms timescale.

**Structure of the TR $\beta$ •T3/apo-RXR $\alpha$  complex.** To further detail the structural mechanism by which TR $\beta$  allosterically silences RXR $\alpha$ , we crystallized apo-RXR $\alpha$  in complex with TR $\beta$ , T3 and a co-activator peptide derived from SRC-2. The anisotropic data set

was scaled to a resolution of 3.2–3.8 Å and refined to an  $R_{\text{work}}/R_{\text{free}}$  of 23.6/28.1% (Table 1). Consistent with other RXR heterodimer structures, TR $\beta$  and RXR $\alpha$  interact via the conserved dimer interface, largely comprised of helix 11 in each monomer, with additional contacts from helices 8 and 10 (Fig. 2a). TR $\beta$  adopts the active conformation when bound to T3, with helix 12 forming one side of the co-activator-binding site, allowing the docking of the SRC-2 peptide. RXR $\alpha$  displays an inactive conformation with no bound ligand or co-activator peptide while helix 12 docks at the AF-2 surface. Although the asymmetric unit of the TR $\beta$ •T3/apo-RXR $\alpha$  complex is a dimer, the crystal packing reveals a heterotetramer assembly (Supplementary Fig. 2).

Compared with other NR heterodimer structures, TR $\beta$ •T3/apo-RXR $\alpha$  displays a more extreme deviation from the C2 (180°) symmetry of the dimer. RXR $\alpha$  helix 7 forms an extensive hydrogen bond network with TR $\beta$  helix 9 (Fig. 2a). However, the symmetry-related RXR $\alpha$  helix 9 and TR $\beta$  helix 7 are further apart by ~3 Å, preventing this sort of interaction. Superposing TR $\beta$  with an RXR $\alpha$  subunit in the homodimer structure clearly revealed that the overall LBD structure is highly conserved (Fig. 2b). However, superposing these two structures via the RXR $\alpha$  protomer of the dimer subunits revealed a dramatic shift in the dimer interface (Fig. 2c). The amino-terminal end of TR $\beta$  helix 11 is oriented similarly towards RXR $\alpha$ , while TR $\beta$  helices 7, 10 and the carboxyl-terminal part of helix 11 are substantially shifted. As discussed below, this altered dimer interface induces conformational changes in RXR $\alpha$ , accounting for its silencing by TR $\beta$ .

**Structural mechanism for silencing of RXR by TR.** The TR $\beta$ •T3/apo-RXR $\alpha$  crystal structure revealed that the structural basis of RXR silencing is via an allosteric signal emanating from the middle of the dimer interface. Compared with other RXR dimers fully occupied by ligands—including the RXR $\alpha$  homodimer<sup>46</sup>, and permissive RXR heterodimer complexes with LXR<sup>47</sup> and PPAR $\gamma$ <sup>48</sup>—our structure of the TR $\beta$ •T3/apo-RXR $\alpha$

heterodimer shows a marked shift in TR $\beta$  helix 11 (Fig. 3a). This shift induces a rotation of RXR $\alpha$  helix 11, which is visualized by comparing our TR $\beta$ •T3/apo-RXR $\alpha$  heterodimer with the RXR $\alpha$  homodimer (Fig. 3b–d) or with the apo-RXR $\alpha$  tetramer (Supplementary Fig. 3). In the N terminus of helix 11, TR $\beta$  T426 is shifted towards RXR $\alpha$  P423 (Fig. 3b), which shows a rotation away from TR $\beta$  in the heterodimer structure (Fig. 3c, Supplementary Fig. 3a). Towards the C terminus of helix 11, TR $\beta$  is shifted away from RXR $\alpha$ , leading to a further rotation of RXR $\alpha$  helix 11 to maintain van der Waals contacts between RXR $\alpha$  L430 and TR $\beta$  helix 11 (Fig. 3d, Supplementary Fig. 3b).

Notably, the TR $\beta$ -directed rotation of RXR $\alpha$  helix 11 in the TR $\beta$ •T3/apo-RXR $\alpha$  structure induces a corresponding rotation of the adjacent RXR helix 5, which in turn disrupts the active conformation of RXR $\alpha$ . In the active conformation of the RXR homodimer, W305 in helix 5 mediates contacts with the bound ligand, M454 in helix 12 and L276 in helix 3, which is part of the AF-2 co-activator-binding surface (Fig. 3e). In contrast, in the TR $\beta$ •T3/apo-RXR $\alpha$  structure TR $\beta$ -induced rotation of RXR $\alpha$  helix 5 in the heterodimer provokes a clash with the active conformation of helix 12 that pushes both L276 in helix 3 and M454 in helix 12 away from W305 in helix 5 (Fig. 3f,g). Importantly, rotation of helix 5 is not observed in the apo-RXR $\alpha$  homotetramer (Supplementary Fig. 3c), and is thus not a consequence of the substantial shift in helix 3 that is observed in both the TR $\beta$ •T3/apo-RXR $\alpha$  and apo-RXR $\alpha$  tetramers, which is rather determined by the tetramer packing. The electron density map allows the clear visualization of the main chain rotation required for interpretation of this data (Supplementary Fig. 3d,e), and the rotation of helix 5 is significant (Supplementary Fig. 4). Thus in the TR $\beta$ •T3/apo-RXR $\alpha$  structure the TR $\beta$ -induced rotation of RXR $\alpha$  helix 11 and helix 5 disables the active conformation of RXR $\alpha$ .

**Structural role of SCA co-evolved amino acids.** Work from the Mangelsdorf and Ranganathan labs<sup>10</sup> identified a network of co-evolved amino acids that are energetically coupled and mediate allosteric signalling in RXR heterodimers. A SCA was used to identify a network of 27 amino acids that comprise an allosteric signalling network for communication between RXR and its heterodimer partner. Importantly, an extensive mutagenesis screen showed that mutation of residues in one molecule allosterically impacted ligand response (that is, permissivity) from the partner<sup>10</sup>, although the structural mechanism that drives this effect at the atomic level remained unknown.


Helix 5 lies at the core of the SCA network, and connects the dimer interface, the ligand-binding pocket and the co-activator-binding site (Fig. 4a,b). This network includes residues in the core of RXR $\alpha$  that promote rotation of helix 5 and subsequent silencing of RXR $\alpha$ , including residues in helix 11 (for example, L425 and R426), helix 5 (for example, E307 and W305) and helix 3 (for example, L276). RXR R426A and W305A mutants, and the analogous mutants in a permissive RXR heterodimer partner afford a dramatic loss-of-function equivalent to helix 12 deletion<sup>10</sup>. However, while RXR E307A (helix 5) has a modest effect on function, its analogous mutation in a permissive RXR heterodimer partner blunts the permissive response with RXR ligand. The rotation of RXR $\alpha$  W305 observed in the TR $\beta$ •T3/apo-RXR $\alpha$  structure would directly impact ligand binding, thereby accounting for the lower affinity of the TR/RXR heterodimer for RXR ligands<sup>34</sup>. The importance of these residues is underscored by the transmission of helix 5 rotation to the co-evolved amino acid residues in helix 3 and helix 4 at the core of the co-activator-binding site (Fig. 4c). Our

**Table 1 | Data collection and refinement statistics.**

| T3-bound TR $\beta$ /SRC-2/apo-RXR $\alpha$ |                      |
|---|----------------------|
| <i>Data collection</i>                      |                      |
| Space group                                 | P 31 2 1             |
| Cell dimensions                             |                      |
| <i>a</i> , <i>b</i> , <i>c</i> (Å)          | 63.25, 63.25 225.81  |
| $\alpha$ , $\beta$ , $\gamma$ (°)           | 90.00, 90.00, 120.00 |
| Resolution (Å)                              | 3.2 (3.31–3.22)*     |
| $R_{\text{merge}}$                          | 0.09 (0.7)           |
| <i>I</i> / $\sigma$ <i>I</i>                | 19.9 (1.46)          |
| Completeness (%)                            | 96.5 (86.2)          |
| Redundancy                                  | 11.1 (5.0)           |
| <i>Refinement</i>                           |                      |
| Resolution (Å)                              | 3.2                  |
| No. of reflections                          | 8,950                |
| $R_{\text{work}}/R_{\text{free}}$           | 0.2365/0.2814        |
| <i>No. of atoms</i>                         |                      |
| Protein                                     | 3,221                |
| Ligand/ion                                  | 23                   |
| Water                                       | 0                    |
| <i>B-factors</i>                            |                      |
| Protein                                     | 132.9                |
| Ligand                                      | 96.1                 |
| <i>R.m.s. deviations</i>                    |                      |
| Bond lengths (Å)                            | 0.004                |
| Bond angles (°)                             | 0.65                 |

R.m.s., root mean squared; RXR, retinoid X receptor.  
\*Data in parenthesis correspond to the highest resolution bin.





**Figure 2 | Crystal structure of the TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  LBD complex.** (a) Structure of the TR/RXR LBD heterodimer is shown as ribbon with T3 as space filled. TR is coloured green, and the bound SRC-2 peptide is coloured blue and only binds to T3•TR. RXR is coloured light blue, with the dimer interface coloured coral and helix 12 coloured purple. There is no bound ligand in RXR, and RXR helix 12 adopts an inactive conformation positioned into the AF-2 co-activator-binding surface. (b) TR is superimposed on the RXR LBD homodimer (PDB 1MVC), showing conservation of domain structure. Structures are coloured as in a. (c) Same as b, except dimers are superimposed via the RXR protomer, rather than TR to RXR, illustrating the shift in the TR dimer interface relative to the other RXR promoter in the RXR homodimer. The magenta circle highlights the only region that superimposes similarly between TR and RXR, the amino-terminal end of TR $\beta$  helix 11.


structural data suggests a model where this co-evolved network controls the rotation of helix 5, thus impacting the dimer interface, and the ligand- and co-activator-binding sites.

In our TR $\beta$ •T3/apo-RXR $\alpha$  heterodimer structure, RXR $\alpha$  ligand binding would require RXR $\alpha$  helix 3 to move back into the agonist conformation, driving RXR $\alpha$  L276 on helix 3 towards RXR $\alpha$  W305 in helix 5, leading to a reversal of the TR $\beta$ -induced rotation of RXR $\alpha$  helix 5. To determine if the conformation of these RXR $\alpha$  regions are affected by TR $\beta$  heterodimerization, we performed differential HDX mass spectrometry comparing RXR $\alpha$  in its homodimeric state versus heterodimerized to TR $\beta$ . In the presence of T3, 9cRA and co-activator peptide, the secondary structural elements of TR $\beta$ -bound RXR $\alpha$  that were protected from amide exchange centred around P423 in helix 11 and extended to L276 in helix 3, relative to RXR $\alpha$  in the homodimer (Fig. 4d and Supplementary Table 1). The changes in HDX support our model where these regions direct allosteric signalling within the heterodimer resulting in the silencing of RXR by TR.

To further test the role of helix 5 rotation in connecting the dimer interface with helix 3, we introduced the RXR $\alpha$  helix 3 mutation L276V, as we hypothesized that the smaller valine residue at this site (Fig. 3f) would facilitate packing of helix 3 against the rotated helix 5, even in the presence of RXR ligand. With the wild-type TR $\beta$ /RXR $\alpha$  heterodimer, 9cRA

impaired T3-mediated induction of a TR-responsive luciferase reporter in CV-1 mammalian cells transfected with TR $\beta$ /RXR $\alpha$ , shown by a highly significant effect of 9cRA in a two-way analysis of variance (ANOVA,  $F(1,42) = 27$ ;  $P < 0.001$ ). There was also a trend towards an interaction between the T3 dose and 9cRA terms, suggesting a potential effect of 9cRA on making T3 less potent (ANOVA,  $F(6,42) = 2$ ;  $P = 0.071$ ). (Fig. 5a). In contrast, the mutated TR $\beta$ /RXR $\alpha$  L276V heterodimer showed a gain-of-function in response to T3 (10- versus 5-fold activation), (ANOVA, WT + T3 versus L276V + T3: L276V effect  $F(1,42) = 67$ ;  $P < 0.0001$ ) and this mutation abolished the inhibitory effect of 9cRA on TR activation (Fig. 5b). These gain-of-function results are consistent with our model, where the interaction between RXR $\alpha$  W305 in helix 5 and L276 in helix 3 contributes towards the allosteric silencing of RXR by TR.


**Role of helix 11 C terminus in cross-dimer signalling.** We also tested the role of helix 11 in modulating the allosteric signal. While our studies here point to roles for the N-terminal region of helix 11 in TR $\beta$  and RXR $\alpha$  in rotating helix 5, we previously noted that the C terminus of helix 11 could be differentially positioned by distinct ligands, thereby controlling the packing of helix 12 in the agonist conformer. This modulation of helix 11



**Figure 3 | TR alters apo-RXR conformation via the helix 11 portion of the dimer interface.** (a) Helix 11 of the dimer interface shown as C $\alpha$  traces for TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$ , coloured green and coral, respectively. The RXR homodimer (PDB 1MVC), RXR/PPAR $\gamma$  (PDB 1FM6) and RXR/LXR (PDB 1UHL) heterodimers were superimposed on the TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  structure using the RXR promoter molecule and are coloured grey. (b–d) The active conformation RXR homodimer (PDB 1MVC) superimposed on the TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  structure via RXR and coloured as in a, with the RXR homodimer coloured grey. (b) TR helix 11 (green) induces a shift in the RXR helix 11 (coral) relative to the RXR homodimer (grey). This shift is adjacent to RXR helix 5. (c) The unique position of TR T426 in helix 11 induces a shift in RXR P423 in helix 11 and a rotation of the RXR helix 11 backbone. (d) The location of TR A433 in helix 11 away from the dimer interface compared with the equivalent residue in RXR, L430, allows RXR L430 and the RXR helical backbone to rotate in context of the TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  heterodimer. (e) RXR in the active conformation (PDB 1MVC) with RXR ligand (MBS649) shown as space filled and SRC-2 peptide bound to the AF-2 co-activator-binding surface coloured red. RXR W305 in helix 5 mediates contacts with the ligand, M454 in helix 12 and the co-activator-binding site via L276 in helix 3. Colour is used to help differentiate secondary structural elements and provide depth for overlapping elements; helix 3 and 4 in cyan, helix 5 in blue, and helix 10/11 and helix 12 in orange. (f) TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  was superimposed with the active conformation RXR homodimer (PDB 1MVC) and shown as C $\alpha$  trace. The rotation of helix 5 in TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  repositions W305 such that it clashes with the active conformation of RXR L276. (g) Same as f, but showing the active conformation of helix 12, and the clash with the rotated position of W305 in the TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  heterodimer.

provides the structural basis for partial agonist activity on NRs, by titrating the dynamics or stability of helix 12 as it forms the active conformer<sup>22,23</sup>. Above we also noted that RXR $\alpha$  E434 can form hydrogen bonds across the dimer interface with some heterodimer partners<sup>13</sup>, right in the plane of the ligands,

suggesting a conduit for structural information from the ligand to the partner receptor. In total, this suggests that the position of RXR $\alpha$  helix 11 can be affected by the dimer partner and modulated by either the RXR ligand or partner ligand. Although the RXR E434 side chain is not visible in our structure, it would




**Figure 4 | Co-evolved amino acid network mediates structural allostery between RXR and TR.** (a) The TRβ•T3•SRC-2/apo-RXRα structure (green and coral) superimposed with the active conformation RXR homodimer (PDB 1MVC) via RXR and shown in grey. RXR residues in helix 11 (L425, R426) and helix 5 (W305, E307) are part of a network of co-evolved amino acids identified using a statistical coupling analysis (SCA). (b) The SCA network amino acids shown as space filled on the TRβ•T3•SRC-2/apo-RXRα heterodimer link the dimer interface, ligand-binding pocket and AF-2 co-activator-binding site. (c) Active conformation RXR homodimer (PDB 1MVC) superimposed with RXR from the TRβ•T3•SRC-2/apo-RXRα heterodimer. Shown are helix 3 and helix 4 of the AF-2 surface, and W305 in helix 5. The rotation of helix 5 induces an altered conformation of the AF-2 surface via the SCA network amino acids. (d) Regions in RXR that are protected from HDX on heterodimerization with TR.

be positioned to potentially interact with TRβ S437 in helix 11. We previously demonstrated a role for this hydrogen bond in signal integration between RAR/RXR heterodimers<sup>21</sup>. Mutation of RXRα E434 to asparagine induced a gain-of-function in response to T3, both in drosophila SL2 cells that lack endogenous RXR and TR (Fig. 5c) and in CV-1 monkey cells (Fig. 5d). Thus, the C terminus of RXRα helix 11 plays a critical role in regulating the response of the TRβ/RXRα heterodimer to T3.

To extend these results, we performed similar experiments with VDR, which is another heterodimer partner that silences RXR. Our HDX analysis of the full-length VDR/RXRα heterodimer with various combinations of ligands, DNA and co-activators established that vitamin D3 ligand induces stabilization of the same RXRα regions found here to be affected by TRβ, including helix 3 and helix 11 (ref. 7). We therefore tested a series of RXRα E434 mutations in complex with VDR, and a mutation of the corresponding residue in VDR, K395 (Fig. 5e). Although RXR ligand has no activity on its own, within the context of the VDR/RXRα heterodimer it is conditionally permissive because it enhances vitamin D3-induced transactivation. The helix 11 mutations selectively modulate the conditional activation by the combination of vitamin D3 and RXR agonists, and lead to both gain- and loss-of-function. Taken together, these data suggest that similar helix 11-mediated mechanisms control allosteric signaling across the dimer interfaces of TR/RXR and VDR/RXR heterodimers, and that there are several mechanisms for heterodimer signal integration.

**Ligand signalling in PPARγ/RXRα employs SCA network.** To determine if ligand-selective signalling can occur between LBDs in RXR heterodimers, we took advantage of our extensive structural and chemical biology efforts with PPARγ to compare ligands that produce different signalling outcomes or graded receptor activation<sup>4,25–27,49</sup>. We performed NMR analysis using isotopically labelled RXRα and unlabelled PPARγ to observe conformational changes in RXRα resulting from ligand binding to PPARγ. We added several PPARγ ligands to the apo-PPARγ/9cRA•RXRα complex (Supplementary Fig. 5); including a full PPARγ agonist (rosiglitazone), a near full agonist (MRL20), a partial agonist (MRL24) and an antagonist/non-agonist (SR1664). Relative to the other liganded states, PPARγ full agonists rosiglitazone and MRL20 caused notable NMR chemical shift changes for RXRα residues at the core of the dimer interface (Fig. 6a,b and Supplementary Fig. 6), including residues in helix 11 (for example, S427, I428, G429 and L430) and helix 7 (for example, T351 and K356). Other more modest NMR resonance shifts are observed in the RXRα dimer interface, including residues at the N terminus of helix 10/11 (for example, Q411 and G413). Importantly, the PPARγ full agonist-induced NMR chemical shift changes for these residues at the core of the dimer interface were less prominent for the partial agonist and antagonist/non-agonist, suggesting these RXRα residues are structural sensors for PPARγ ligand activity. Thus, the RXRα dimer interface responds to PPARγ ligands in a manner that tracks with the ligand pharmacology, ranging from full agonist to non-agonist.



**Figure 5 | Mutagenesis confirms a structure-function role for co-evolved amino acids.** (a,b) CV-1 cells co-transfected with TR $\beta$  expression plasmid, (a) RXR $\alpha$  or (b) RXR $\alpha$  L276V mutant expression plasmid, and a TR-responsive luciferase reporter. Cells were treated with vehicle, or the indicated dose of T3  $\pm$  1  $\mu$ M 9cRA for 24 h. (c) Drosophila SL2 cells co-transfected with TR $\beta$  expression plasmid, RXR $\alpha$  or RXR $\alpha$  E434N mutant expression plasmid, a TR-responsive luciferase reporter. Cells were treated with vehicle, the RXR agonist LG100268 (LG268; 100 nM) and/or 1  $\mu$ M TR agonist (T3) for 24 h. (d) CV-1 cells co-transfected with TR $\beta$  expression plasmid, RXR $\alpha$  or RXR $\alpha$  E434N mutant expression plasmid, and a TR-responsive luciferase reporter. Cells were treated with vehicle or the indicated dose of T3 overnight. (e) Drosophila SL2 cells co-transfected with VDR expression plasmid, RXR $\alpha$  or RXR $\alpha$  E434N mutant expression plasmid, and a VDR-responsive luciferase reporter. Cells were treated with vehicle, the RXR agonist LG100268 (LG268; 100 nM) and/or 1  $\mu$ M VDR agonist (vitamin D3) for 24 h. Luciferase activity is shown normalized to vehicle-treated cells and was performed in quadruplicate; plotted with the average  $\pm$  s.e.m and representative of at least three experiments.

A possible mechanism for this allosteric communication through the RXR $\alpha$  dimer interface involves the C terminus of PPAR $\gamma$  helix 12. We previously demonstrated that PPAR $\gamma$  agonists, but not partial agonists or antagonists, stabilize helix 12 of PPAR $\gamma$ <sup>4,25–27</sup>. In the PPAR $\gamma$ /RXR $\alpha$  heterodimer crystal structure<sup>50</sup>, RXR $\alpha$  K431 in helix 11 forms a hydrogen bond with PPAR $\gamma$  Y477, the most C-terminal residue in PPAR $\gamma$ . RXR $\alpha$  residues affected differently by the graded PPAR $\gamma$  ligands are structurally close to this region. Thus, the effect of PPAR $\gamma$  full agonists on RXR $\alpha$  residues in the dimer interface are likely mediated through stabilization of PPAR $\gamma$  helix 12 and its interaction with RXR $\alpha$ .


However, structural perturbations also penetrate into other regions of RXR $\alpha$ , including the hydrophobic core, ligand-binding pocket and the AF-2 surface. This includes effects on RXR $\alpha$  core residues in helix 5 and helix 7 (for example, G304, E307, A311 and L353) (Fig. 6b and Supplementary Fig. 6). One of two tryptophan residues in the RXR $\alpha$  LBD core (W305 or W282) is also affected. Helix 5 sits between helix 11 and helix 3 at the nexus of the ligand-binding pocket and the AF-2 surface. The perturbed residues provide a direct connection to structural changes in helix 3, the AF-2 surface and the ligand-binding pocket (Fig. 6c and Supplementary Fig. 6). This includes small, but notable changes in RXR $\alpha$  helix 3 residue L276, as well as AF-2 surface residues K284 and S290, which are part of a region that forms electrostatic interactions with the bound co-activator peptide in the crystal structures. Thus, RXR $\alpha$  helix 5 is a key part of the LBD core that

transmits PPAR $\gamma$  ligand-induced allosteric signals from the dimer interface to the RXR $\alpha$  ligand-binding pocket and the AF-2 surface.

An additional region of the RXR $\alpha$  LBD core, helix 9, also mediates PPAR $\gamma$  ligand-induced allosteric signalling across the dimer interface in a similar direction. Helix 9 forms part of the core that contacts the dimer interface, and stabilizes the AF-2 surface via interaction with helix 3 and helix 4 residues. PPAR $\gamma$  ligand-induced NMR chemical shift changes in RXR $\alpha$  helix 11 (for example, Q411 and G413) and helix 9 (for example, G368), which lie in this region, suggest that helix 9 may also transmit allosteric information from the dimer interface to the AF-2 surface. Additional NMR resonances showing specific changes in response to PPAR $\gamma$  ligands include A457 at the C terminus of RXR $\alpha$  helix 12 and A327 in the RXR $\alpha$  ligand-binding pocket.

All together, our NMR data reveal that binding of different ligands to its heterodimer partner, PPAR $\gamma$ , can cause subtle but significant changes in the conformation of RXR $\alpha$ . Using HDX mass spectrometry, we confirmed that ligand binding to PPAR $\gamma$  imparts structural changes in RXR $\alpha$  (Supplementary Fig. 7 and Supplementary Table 2). These effects are not only present at the dimer interface, but also extend through the core of the RXR $\alpha$  LBD, to the AF-2 surface, helix 12 and the ligand-binding pocket. As we discuss below, these structural regions involve a network of co-evolved amino acids in NRs, which are energetically coupled and mediate allosteric signalling in RXR heterodimers.





**Figure 6 | NMR reveals ligand binding to PPAR $\gamma$  affects the conformation of RXR.** NMR data are coloured grey for 9cRA-bound RXR $\alpha$ ; black for 9cRA-bound RXR $\alpha$  heterodimerized to apo-PPAR $\gamma$  or the same bound to the following PPAR $\gamma$  ligands: rosiglitazone (magenta), MRL20 (blue), MRL24 (orange) or SR1664 (green); plotted on PPAR $\gamma$ /RXR $\alpha$  (PDB 1FM9). **(a)** NMR data (left) focusing on residues in RXR $\alpha$  helix 7 and helix 10/11 dimer interface that are perturbed by ligand binding to PPAR $\gamma$ , which are plotted onto the PPAR $\gamma$ /RXR $\alpha$  crystal structure and coloured according to structural location (yellow for helix 7; blue for helix 10/11); coloured dark if shown in the NMR data to the left or light if not. **(b)** NMR data (left) focusing on residues in core of RXR $\alpha$  that are perturbed by ligand binding to PPAR $\gamma$ , which are plotted onto the PPAR $\gamma$ /RXR $\alpha$  crystal structure and coloured red; and coloured dark if shown in the NMR data to the left or light if not. **(c)** NMR data (left) focusing on residues in RXR $\alpha$  helix 12, the AF-2 surface and the ligand-binding pocket that are perturbed by ligand binding to PPAR $\gamma$ , which are plotted onto the PPAR $\gamma$ /RXR $\alpha$  crystal structure and coloured according to structural location (green for AF-2/helix 12; orange for the ligand-binding pocket); coloured dark if shown in the NMR data to the left or light if not.


**Conservation of allosteric signalling through helix 5.** Our data support a model where TR-induced rotation of RXR helix 5 drives TR silencing of RXR, and where rotation in the other direction drives the inhibitory effects of 9cRA on TR via the dimer interface. We propose that the co-evolved amino acid network lies at the core of this allosteric mechanism, which is consistent with our mutagenesis screen showing that these co-evolved amino acids impact allosteric signalling in RXR heterodimers<sup>10</sup>. Indeed, when we calculated NMR chemical shift differences between PPAR $\gamma$  as a monomer versus heterodimerized to RXR $\alpha$ <sup>51</sup>, structural perturbations were observed in the regions of the evolutionarily conserved residues in helix 11 and helix 5 induced by heterodimerization with RXR $\alpha$  (Fig. 7a).

If an evolutionarily conserved allosteric network directs helix 5 rotation, then it should manifest for other NRs. A comparison of the structures of the LXR homodimer with the permissive LXR/RXR heterodimer in the presence of co-activator peptide also shows that RXR induces a shift in LXR helix 11 that is transmitted through helix 5, again via the co-evolved amino acid network (Fig. 7b,c). This shift accommodates a flip of LXR W443 in helix 12 into a position against I295 in helix 5 (Fig. 7c) with additional van der Waals interactions and greater buried surface area, thereby stabilizing LXR helix 12 in the agonist conformation. Thus, RXR-induced rotation of LXR helix 5 is also the mechanism through which RXR drives co-activator binding to apo-LXR, a previously unexplained allosteric phenomena in heterodimer signalling<sup>52</sup>. This mechanism is also operational for heterodimers versus monomers of the RAR and the constitutive androstane receptor (Supplementary Fig. 8), supporting a general role for helix 5 rotation in allosteric control of RXR heterodimers. Thus, helix 5 rotation and the evolutionarily conserved SCA network of amino acid residues provide a structural conduit for signalling from the dimer partner, through helix 11, to the ligand-binding pocket and co-regulator-binding surface.

## Discussion


While originally conceived as an on/off switch in transcriptional regulation, it is now clear that NRs contain a number of allosteric fine-tuning mechanisms that allow a full range of graded signalling outcomes. NRs can be viewed more generally as dynamic scaffold proteins, where post-translational modifications and interaction with ligands, co-regulators and DNA modify the nature of the scaffold and the signalling outcomes<sup>5,11</sup>. A large body of work has described functional interactions between NR domains and these interacting molecules, which in sum define a NR signalling code<sup>2,14</sup>. Several studies have investigated various aspects of permissiveness in RXR heterodimers<sup>33,53–55</sup>. However, most of the structural features for allosteric signal integration have remained a mystery, limited in part by our insufficient structural understanding of signalling within the individual domains.

Here we used a variety of structural and functional approaches to show how the dimer partner controls the permissivity, or activity, of RXR $\alpha$  in the integration of two distinct ligand-regulated receptors into a single transcriptional response using residues comprising the SCA network (Fig. 8a). Using NMR and crystallography, we show that structural differences in RXR $\alpha$  affected by the different dimer partners, TR $\beta$  and PPAR $\gamma$ , initiate distinct allosteric signals that suppress or permit modulation of heterodimer activity through RXR $\alpha$ . These signals are transmitted through amino acid residues including the co-evolved network previously identified by SCA<sup>10</sup>. Our NMR data reveal that in the presence of RXR agonist, dimerization with apo-TR $\beta$  triggers a considerable change that reinstates an RXR $\alpha$  conformation that exchanges between two or more conformations on the  $\mu$ s–ms timescale. When compared with activated RXR homodimer<sup>46</sup> and



**Figure 7 | Co-evolved amino acid network with other receptors.** (a) NMR chemical shift perturbations in PPAR $\gamma$  on heterodimerization with RXR $\alpha$  mapped onto the structure of the PPAR $\gamma$  LBD (PDB 2PRG). (b) LXR homodimer (PDB 3IPU) coloured grey and superimposed with the LXR promoter from the LXR/RXR heterodimer (PDB 1UHL) coloured green and coral, respectively, shows that RXR induces rotation of LXR helix 11. (c) The RXR-induced shift in LXR helix 11 (PDB 1UHL) induces a rotation of LXR helix 5 relative to the LXR homodimer (PDB 3IPU), allowing W443 in helix 12 to adopt an alternative conformation with greater van der Waals contacts and increased buried surface area.

permissive RXR heterodimer structures, LXR/RXR<sup>47</sup> and PPAR/RXR<sup>48</sup>, our TR $\beta$ •T3/apo-RXR $\alpha$  crystal structure suggests that dimerization with the non-permissive partner TR $\beta$  rotates RXR $\alpha$  helix 11, twists helix 5, drives open the ligand-binding pocket and



**Figure 8 | Summary of structural studies and allostery in RXR**

**heterodimers.** (a) The SCA network residues plotted on RXR using the PPAR $\gamma$ /RXR $\alpha$  heterodimer structure as a model (PDB 1FM6). (b) Schematic diagram summarizing our TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  crystal structure showing how TR structurally silences RXR. The signal that emanates from TR (i) induces a shift in RXR helix 11 (ii), leading to a rotation of helix 5 (iii) resulting in structural arrangements that cause RXR helix 12 to adopt an inactive conformation (iv). (c) Summary of residues affected in the NMR analysis of ligand-selective signalling in PPAR $\gamma$ /RXR $\alpha$ , plotted on PDB 1FM6. Helix numbers are indicated for elements of interest. Arrows indicate the flow of the allosteric signal.

induces the apo conformer of RXR $\alpha$  (Fig. 8b). This may account for the observation that TR lowers the affinity of RXR $\alpha$  for its ligand<sup>34</sup>. However, this conformational relay mechanism also operates in reverse, mediating the intrinsic activity of the apo-LXR/RXR heterodimer<sup>52</sup>. Here binding of RXR to LXR leads to a compensatory rotation of LXR helix 5, which directly stabilizes LXR helix 12 in the active conformation. Our studies reveal helix 5 as a central locus for allosteric control between the

dimer interface, helix 12, ligand-binding pocket and AF-2 surface. The helices that comprise the SCA network act like a set of interlocking gears to integrate information from the functionally important sites in the NR LBD.

We identified a number of distinct routes for signal transduction through the dimer interface. For example, in our NMR studies of ligand-selective signalling in PPAR $\gamma$ /RXR $\alpha$ , only full agonists of PPAR $\gamma$ , which stabilize helix 12 in the agonist conformation, induce significant alterations in the RXR $\alpha$  dimer interface adjacent to the C terminus of PPAR $\gamma$  helix 12. In this way, RXR $\alpha$  is able to ‘feel’ the position of the partner helix 12 and the degree of partner agonist activity. These types of cross-dimer interactions may also help stabilize helix 12 of the heterodimer partner in the active conformation, as previously suggested<sup>48</sup>. A second set of RXR $\alpha$  regions affected by all of the various PPAR $\gamma$  liganded states include the hydrophobic core, helices 8–10 and helices 3–4 of the AF-2 surface (Fig. 8c). These regions in general employ the network of co-evolved residues predicted by SCA. Of these, PPAR $\gamma$  full agonists appear to cause a more prominent effect, but the specific role of this structural conduit is not clear. It could mean that PPAR $\gamma$  full agonists may provide additional stabilization to the RXR $\alpha$  AF-2 surface, or alter the shape of the AF-2 to give preferences for certain co-activators. Our NMR data further suggests that this interlocking relay system is also modulated by the ligand, as one of the two tryptophan residues in the RXR LBD, W305 in helix 5 or W282 in helix 3, was differentially sensitive to PPAR ligands. We thus envision that structural elements in helix 5 of RXR and the dimer partner can move in a coordinated way with the C-terminal region of the helix 11 dimer interface to coordinate both receptor- and ligand-specific signals into an integrated transcriptional response with the co-evolved amino acids playing a primary role.

We identified the C terminus of helix 11, adjacent to the bound ligands, as also contributing to heterodimer signalling. Within each monomer, there are two known mechanisms through which different ligands can produce a range of signalling outcomes from full agonist to antagonist. One is by direct modulation of helix 12, where the physical contact between ligand and helix 12 determines the percentage of time the active conformation of helix 12 is stabilized, docked across helix 3 and helix 11 to form the AF-2 surface. A second mechanism—indirect modulation—occurs when the ligand can position helix 11 so as to provide suboptimal van der Waals packing with helix 12, and thus indirectly control its stability in the agonist conformation<sup>21–24</sup>. Our data suggest an extension of this model where the position of helix 11 is also controlled by the heterodimer partner helix 11. Our mutagenesis data further suggests that the C terminus of helix 11 is also positioned by the type of dimer partner, in addition to the specific ligand, contributing to permissive versus non-permissive heterodimer signal integration.

## Methods

**Protein expression, purification and ligands.** Human RXR $\alpha$  LBD (amino acids 223–462), human TR $\beta$  LBD (residues 202–461) and human PPAR $\gamma$  LBD (residues 203–477; isoform 1 numbering) were cloned into a pET vector with a ligation-independent cloning site as TEV-cleavable hexahistidine-tagged (His-tag) fusion proteins. RXR $\alpha$  LBD was induced in BL21(DE3) cells, and purified with immobilized nickel affinity chromatography. The eluted protein was mixed with a 1:30 ratio (by mg weight) of His-tag TEV protease and dialysed overnight in 20 mM Tris pH 8, 50 mM NaCl, 50 mM  $\beta$ -mercaptoethanol and 10% glycerol. The protein solution was again purified using immobilized nickel affinity chromatography to remove uncut protein, the cut His-tag and the TEV protease. The flow through was diluted 2  $\times$  in H<sub>2</sub>O and subjected to gel filtration in buffer consisting of 20 mM Tris 8.0, 50 mM NaCl, 10% glycerol and 5 mM  $\beta$ -mercaptoethanol. TR $\beta$  LBD was induced in BL21(DE3)/Rosetta cells, and purified with immobilized nickel affinity chromatography (Qiagen) in a manner identical to that of RXR $\alpha$ . For crystallography, purified TR $\beta$  LBD that had not been subjected to TEV proteolysis was incubated with purified RXR lacking a His-tag (at a ratio of 2:1 RXR to TR). The complex was purified with immobilized nickel affinity chromatography using



buffers and gradients as described above and then the TR LBD His-tag was removed by proteolysis with TEV protease overnight while the complex was being dialysed to 20 mM Tris 8.0, 150 mM NaCl, 5 mM BME and 10% glycerol. PPAR $\gamma$  LBD was expressed and purified using similar methods, and final NMR sample conditions contained 20 mM KPO $_4$  (pH 7.4) and 50 mM KCl<sup>56</sup>. Ligands were purchased from commercial sources, or in the case of MRL20, MRL24 and SR1664 were synthesized<sup>27,57</sup>.

**NMR spectroscopy and analysis.** NMR data were collected at 298 K on a 700 MHz Bruker NMR instrument equipped with a conventional TXI triple resonance probe and on a 800-MHz Varian NMR instrument equipped with a cryogenically cooled triple resonance probe. Ligands that were added to proteins were dissolved in DMSO- $d_6$ . NMR experiments were performed using pulse sequences and standard experimental parameters provided with Bruker Topspin 3.0. RXR $\alpha$  LBD chemical shift assignments<sup>37</sup> were validated and/or transferred to various complexed states using standard 2D and 3D NMR TROSY-based methods, including HSQC, HNCOC, HNCA, HN(CO)CA and HN(CA)CB and <sup>15</sup>N-NOESY-HSQC experiments. Data were processed using Bruker Topspin 3.0 or NMRPipe<sup>58</sup> and analysed with NMRView<sup>59</sup>. NMR chemical shift perturbations ( $\Delta\delta$ CSP) for PPAR $\gamma$  LBD in the monomer form and heterodimerized to RXR $\alpha$  LBD were calculated from published values<sup>51</sup> as follows:  $\Delta\delta$ CSP =  $|\Delta\delta$ HN| + (0.154  $\times$   $|\Delta\delta$ N|) + (0.341  $\times$   $|\Delta\delta$ C'|); with  $\Delta\delta$ HN,  $\Delta\delta$ N and  $\Delta\delta$ C' as the backbone <sup>1</sup>H $_N$ , <sup>15</sup>N and <sup>13</sup>C' (carbonyl) NMR chemical shift differences between monomer and heterodimer, respectively, and mapped onto the PPAR $\gamma$  LBD crystal structure (PDB 2PRG).

**Crystallization, structure determination and refinement.** The TR $\beta$ •T3•SRC-2/apo-RXR $\alpha$  complex was formed by mixing a threefold molar excess of T3 (Sigma) and SRC-2 peptide (HKILHRLI). Crystal trials were initially conducted using commercially available sparse matrix screens, from which microcrystals were identified and subsequently streak seeded to produce a high resolution diffracting crystal. The well solution consisted of 20% PEG 3350, 100 mM Tris pH 8.0, 0.1 M ammonium acetate and 1 mM 11-Methoxy-3,7,11-trimethyl-2E,4E-dodecadienoic acid. The crystal was flash cooled with liquid nitrogen after briefly immersing in paratone-n as a cryo-protectant. Data was collected at SSRL beamline 11-1 at 100 K. The structure was solved with molecular replacement using Phaser<sup>60</sup> using search models for TR (PDB 3GWS) and RXR (PDB 1G5Y). Initially scaled at 3.5 Å, the model was refined using PHENIX<sup>61</sup> to an  $R_{\text{free}}$  of 33%. The data set was anisotropic and was therefore rescaled to 3.2 Å and truncated to 3.2  $\times$  3.8 Å based on a 1.5 signal-to-noise ( $\sigma$ ) cut-off using the UCLA Diffraction Anisotropy Server<sup>62</sup>. This allowed the refinement to lower the  $R_{\text{work}}/R_{\text{free}}$  to 23.6/28.1%. The reported Rmerge for our structure is from the pre-truncated data set and was not used to determine the resolution cut-off. Instead, an anisotropic cut-off of 1.5 $\sigma$  was used based on recommendations of Brunger *et al.*<sup>63,64</sup> to avoid discarding reflections when working with low resolution structures and with modern refinement practices that can accommodate lower signal reflections. Thus, the very good  $R_{\text{free}}$  and geometry statistics for this resolution likely reflect the use of higher resolution structures for molecular replacement. The TLSMD server was used to identify optimal TLS groups<sup>65</sup>. The model was rebuilt using COOT<sup>66</sup>. Structural figures were generated with CCP4MG<sup>67</sup>.

**HDX mass spectrometry.** HDX was performed using a fully automated in-house system<sup>49,68</sup> with some modifications. Briefly, protein samples are incubated with D $_2$ O-containing buffer at 4 °C for 10, 30, 60, 900 and 3,600 s. Following on-exchange, forward or back exchange was minimized and the protein was denatured by dilution with 25  $\mu$ l of quench solution (0.1% v/v trifluoroacetic acid/TFA in 3 M urea). Samples were then passed through an immobilized pepsin column (prepared in-house) at 50  $\mu$ l min<sup>-1</sup> (0.1% v/v TFA, 15 °C) and the resulting peptides were trapped on a C $_8$  trap column (Hypersil Gold, Thermo Fisher). The bound peptides were then gradient eluted (5–50% CH $_3$ CN w/v and 0.3% w/v formic acid) across a 2  $\times$  50-mm C $_18$  HPLC column (Hypersil Gold) for 5 min at 4 °C. The eluted peptides were then subjected to electrospray ionization directly coupled to a high resolution Orbitrap mass spectrometer; Exactive for TR/RXR or QExactive for PPAR $\gamma$ /RXR (Thermo Fisher Scientific). For TR/RXR measurements, 4  $\mu$ l of 10  $\mu$ M protein was diluted to 20  $\mu$ l of D $_2$ O buffer. Following the prescribed on-exchange interval, the reaction was quenched with a cold 3-M urea solution containing 1% TFA and 50 mM TCEP. For PPAR $\gamma$ /RXR measurements, 10  $\mu$ M of HIS-PPAR $\gamma$  LBD protein (20 mM KPO $_4$  pH 7.4, 50 mM KCl) in complex with 10  $\mu$ M FLAG-RXR LBD (20 mM KPO $_4$  pH 7.4, 50 mM KCl) was preincubated with 1:2 molar excess of compound. About 5  $\mu$ l of protein solution was mixed with 20  $\mu$ l of D $_2$ O-containing buffer (20 mM KPO $_4$  pH 7.4, 50 mM KCl) to initiate on-exchange. Following on-exchange, forward or back exchange was minimized and the protein was denatured by dilution with 25  $\mu$ l of quench solution (0.1% v/v TFA in 3 M urea). HDX values are the average of three individual on-exchange experiments acquired in a random order. HDX data analysis was performed with 'HDX Desktop' for TR/RXR samples and 'HDX Workbench' for PPAR $\gamma$ /RXR<sup>69,70</sup>. Each HDX experiment was carried out in triplicate and the intensity-weighted average  $m/z$  value (centroid) of each peptide isotopic envelope was calculated. Data-dependent tandem mass spectrometry was performed in the absence of exposure to deuterium for peptide identification in a separate experiment using a 60-min

gradient. Peptides with a Mascot score of  $\geq 20$  were included in the peptide sets used for HDX.

**Cell culture and luciferase co-transfection assays.** CV-1 cells (ATCC) were maintained in DMEM (Invitrogen) with 10% FBS charcoal/dextran-treated (Hyclone). Cells were transfected using Fugene HD (Roche) with a DR-4 luciferase reporter with expression plasmids for RXR $\alpha$  and TR $\beta$ . After 6 h, cells were passaged and transferred into 384-well plates. Ligands were added the next day and allowed to incubate overnight before processing for luciferase activity. An equal volume of Britelite (PerkinElmer) was dispensed and the luminescence was measured on an Analyst GT plate reader (PerkinElmer). Drosophila SL2 cells (ATCC) were maintained in Schneider Drosophila Medium (Gibco) containing 5% dextran-charcoal-stripped FBS and transfected at a density of 6,500 cells per well in 96-well plates by calcium phosphate co-precipitation. Co-transfection experiments included 50 ng of reporter plasmid, 20 ng of  $\beta$ -galactosidase expression plasmid, 15 ng of each receptor expression plasmid and PGEM carrier DNA to give a total of 150 ng of DNA per well of a 96-well plate. Cells were transfected for 8 h and were treated for 18 h before harvesting and determination of luciferase and  $\beta$ -galactosidase activity. Luciferase data were normalized to the internal  $\beta$ -galactosidase control and represent the mean of triplicate assays plus s.e. Fold induction values were calculated as ligand-induced relative luciferase units/control relative luciferase units and propagated errors were calculated. Experiments used human full-length RXR $\alpha$ , TR $\beta$ , PPAR $\gamma$  and VDR expression plasmids with the appropriate luciferase reporter plasmid<sup>10</sup>, including TRE2-luc (TR-luc), PPRE3-luc (PPAR-luc) or ADH-mSp3-luc (VDR-luc). RXR mutant expression plasmids were generated using the Stratagene QuikChange Site-Directed Mutagenesis kit and verified by DNA sequencing. Statistical analyses were performed with Graphpad Prism.

## References

- Shulman, A. I. & Mangelsdorf, D. J. Retinoid x receptor heterodimers in the metabolic syndrome. *N. Engl. J. Med.* **353**, 604–615 (2005).
- Rosenfeld, M. G., Lunyak, V. V. & Glass, C. K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. *Genes Dev.* **20**, 1405–1428 (2006).
- Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. *Science* **295**, 2465–2468 (2002).
- Choi, J. H. *et al.* Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. *Nature* **466**, 451–456 (2010).
- Marciano, D. P. *et al.* The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARgamma, RORs, and Rev-erbs. *Cell Metab.* **19**, 193–208 (2014).
- Meijsing, S. H. *et al.* DNA binding site sequence directs glucocorticoid receptor structure and activity. *Science* **324**, 407–410 (2009).
- Zhang, J. *et al.* DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. *Nat. Struct. Mol. Biol.* **18**, 556–563 (2011).
- Watson, L. C. *et al.* The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. *Nat. Struct. Mol. Biol.* **20**, 876–883 (2013).
- Zhang, J., Hu, X. & Lazar, M. A. A novel role for helix 12 of retinoid X receptor in regulating repression. *Mol. Cell Biol.* **19**, 6448–6457 (1999).
- Shulman, A. I., Larson, C., Mangelsdorf, D. J. & Ranganathan, R. Structural determinants of allosteric ligand activation in RXR heterodimers. *Cell* **116**, 417–429 (2004).
- Nwachukwu, J. C. & Nettles, K. W. The nuclear receptor signalling scaffold: insights from full-length structures. *EMBO J.* **31**, 251–253 (2012).
- Rastinejad, F., Ollendorff, V. & Polikarpov, I. Nuclear receptor full-length architectures: confronting myth and illusion with high resolution. *Trends Biochem. Sci.* **40**, 16–24 (2015).
- Nettles, K. W. & Greene, G. L. Ligand control of coregulator recruitment to nuclear receptors. *Annu. Rev. Physiol.* **67**, 309–333 (2005).
- Huang, P., Chandra, V. & Rastinejad, F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. *Annu. Rev. Physiol.* **72**, 247–272 (2010).
- Shiau, A. K. *et al.* The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* **95**, 927–937 (1998).
- Darimont, B. D. *et al.* Structure and specificity of nuclear receptor-coactivator interactions. *Genes Dev.* **12**, 3343–3356 (1998).
- Renaud, J. P. *et al.* Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. *Nature* **378**, 681–689 (1995).
- Chandra, V. *et al.* Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. *Nature* **456**, 350–356 (2008).
- Xu, H. E. *et al.* Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. *Nature* **415**, 813–817 (2002).
- Brzozowski, A. M. *et al.* Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* **389**, 753–758 (1997).



21. Nettles, K. W. *et al.* Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. *Mol. Cell* **13**, 317–327 (2004).
22. Shiau, A. K. *et al.* Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. *Nat. Struct. Biol.* **9**, 359–364 (2002).
23. Bruning, J. B. *et al.* Coupling of receptor conformation and ligand orientation determine graded activity. *Nat. Chem. Biol.* **6**, 837–843 (2010).
24. Nettles, K. W. *et al.* NF $\kappa$ B selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. *Nat. Chem. Biol.* **4**, 241–247 (2008).
25. Hughes, T. S. *et al.* Ligand and receptor dynamics contribute to the mechanism of graded PPAR $\gamma$  agonism. *Structure* **20**, 139–150 (2012).
26. Bruning, J. B. *et al.* Partial agonists activate PPAR $\gamma$  using a helix 12 independent mechanism. *Structure* **15**, 1258–1271 (2007).
27. Choi, J. H. *et al.* Antidiabetic actions of a non-agonist PPAR $\gamma$  ligand blocking Cdk5-mediated phosphorylation. *Nature* **477**, 477–481 (2011).
28. Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. *Nature* **415**, 187–192 (2002).
29. Pogenberg, V. *et al.* Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. *J. Biol. Chem.* **280**, 1625–1633 (2005).
30. Schulman, I. G., Li, C., Schwabe, J. W. & Evans, R. M. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. *Genes Dev.* **11**, 299–308 (1997).
31. Willy, P. J. & Mangelsdorf, D. J. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. *Genes Dev.* **11**, 289–298 (1997).
32. Westin, S. *et al.* Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. *Nature* **395**, 199–202 (1998).
33. DiRenzo, J. *et al.* Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. *Mol. Cell. Biol.* **17**, 2166–2176 (1997).
34. Forman, B. M., Umeson, K., Chen, J. & Evans, R. M. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. *Cell* **81**, 541–550 (1995).
35. Castillo, A. I. *et al.* A permissive retinoid X receptor/thyroid hormone receptor heterodimer allows stimulation of prolactin gene transcription by thyroid hormone and 9cRA. *Mol. Cell. Biol.* **24**, 502–513 (2004).
36. Li, D., Li, T., Wang, F., Tian, H. & Samuels, H. H. Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor/RXR heterodimer. *Mol. Cell. Biol.* **22**, 5782–5792 (2002).
37. Lu, J., Cistola, D. P. & Li, E. Analysis of ligand binding and protein dynamics of human retinoid X receptor alpha ligand-binding domain by nuclear magnetic resonance. *Biochemistry* **45**, 1629–1639 (2006).
38. Nagy, L. & Schwabe, J. W. Mechanism of the nuclear receptor molecular switch. *Trends Biochem. Sci.* **29**, 317–324 (2004).
39. Kojetin, D. & Burris, T. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. *Mol. Pharmacol.* **83**, 1–8 (2012).
40. Yan, X., Broderick, D., Leid, M. E., Schimerlik, M. I. & Deinzer, M. L. Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry. *Biochemistry* **43**, 909–917 (2004).
41. Yan, X. *et al.* Investigation of ligand interactions with human RXR $\alpha$  by hydrogen/deuterium exchange and mass spectrometry. *J. Am. Soc. Mass Spectrom.* **17**, 1510–1517 (2006).
42. Yan, X. *et al.* Deuterium exchange and mass spectrometry reveal the interaction differences of two synthetic modulators of RXR $\alpha$  LBD. *Protein Sci.* **16**, 2491–2501 (2007).
43. Singarapu, K. K. *et al.* Ligand-specific structural changes in the vitamin D receptor in solution. *Biochemistry* **50**, 11025–11033 (2011).
44. Zhang, J. *et al.* Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. *Structure* **18**, 1332–1341 (2010).
45. Wright, E. *et al.* Helix 11 dynamics is critical for constitutive androstane receptor activity. *Structure* **19**, 37–44 (2011).
46. Egea, P. F., Mitschler, A. & Moras, D. Molecular recognition of agonist ligands by RXRs. *Mol. Endocrinol.* **16**, 987–997 (2002).
47. Svensson, S. *et al.* Crystal structure of the heterodimeric complex of LXR $\alpha$  and RXR $\beta$  ligand-binding domains in a fully agonistic conformation. *EMBO J.* **22**, 4625–4633 (2003).
48. Gampe, Jr. R. T. *et al.* Asymmetry in the PPAR $\gamma$ /RXR $\alpha$  crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. *Mol. Cell* **5**, 545–555 (2000).
49. Chalmers, M. J. *et al.* Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. *Anal. Chem.* **78**, 1005–1014 (2006).
50. Gampe, Jr. R. T. *et al.* Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. *Genes Dev.* **14**, 2229–2241 (2000).
51. Lu, J., Chen, M., Stanley, S. E. & Li, E. Effect of heterodimer partner RXR $\alpha$  on PPAR $\gamma$  activation function-2 helix in solution. *Biochem. Biophys. Res. Commun.* **365**, 42–46 (2008).
52. Wiebel, F. F. & Gustafsson, J. A. Heterodimeric interaction between retinoid X receptor alpha and orphan nuclear receptor OR1 reveals dimerization-induced activation as a novel mechanism of nuclear receptor activation. *Mol. Cell. Biol.* **17**, 3977–3986 (1997).
53. Li, D., Yamada, T., Wang, F., Vulin, A. I. & Samuels, H. H. Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/RXR heterodimer. *J. Biol. Chem.* **279**, 7427–7437 (2004).
54. Perez, E., Bourguet, W., Gronemeyer, H. & de Lera, A. R. Modulation of RXR function through ligand design. *Biochim. Biophys. Acta* **1821**, 57–69 (2012).
55. Venalainen, T., Molnar, F., Oostenbrink, C., Carlberg, C. & Perakyla, M. Molecular mechanism of allosteric communication in the human PPAR $\alpha$ -RXR $\alpha$  heterodimer. *Proteins* **78**, 873–887 (2010).
56. Hughes, T. S. *et al.* An alternate binding site for PPAR $\gamma$  ligands. *Nat Commun* **5**, 3571 (2014).
57. Acton, 3rd J. J. *et al.* Benzoyl 2-methyl indoles as selective PPAR $\gamma$  modulators. *Bioorg. Med. Chem. Lett.* **15**, 357–362 (2005).
58. Delaglio, F. *et al.* NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* **6**, 277–293 (1995).
59. Johnson, B. A. Using NMRView to visualize and analyze the NMR spectra of macromolecules. *Methods Mol. Biol.* **278**, 313–352 (2004).
60. McCoy, A. J. *et al.* Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674 (2007).
61. Adams, P. D. *et al.* PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr. D Biol. Crystallogr.* **58**, 1948–1954 (2002).
62. Strong, M. *et al.* Toward the structural genomics of complexes: crystal structure of a PE/PEP protein complex from *Mycobacterium tuberculosis*. *Proc. Natl Acad. Sci. USA* **103**, 8060–8065 (2006).
63. Brunger, A. T., DeLaBarre, B., Davies, J. M. & Weis, W. I. X-ray structure determination at low resolution. *Acta Crystallogr. D Biol. Crystallogr.* **65**, 128–133 (2009).
64. DeLaBarre, B. & Brunger, A. T. Considerations for the refinement of low-resolution crystal structures. *Acta Crystallogr. D Biol. Crystallogr.* **62**, 923–932 (2006).
65. Painter, J. & Merritt, E. A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. *Acta Crystallogr. D Biol. Crystallogr.* **62**, 439–450 (2006).
66. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132 (2004).
67. McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. Presenting your structures: the CCP4mg molecular-graphics software. *Acta Crystallogr. D Biol. Crystallogr.* **67**, 386–394 (2011).
68. Chalmers, M. J. *et al.* Methods for the analysis of high precision differential hydrogen deuterium exchange data. *Int. J. Mass Spectrom.* **302**, 59–68 (2011).
69. Pascal, B. D. *et al.* HDX workbench: software for the analysis of H/D exchange MS data. *J. Am. Soc. Mass Spectrom.* **23**, 1512–1521 (2012).
70. Pascal, B. D., Chalmers, M. J., Busby, S. A. & Griffin, P. R. HD desktop: an integrated platform for the analysis and visualization of H/D exchange data. *J. Am. Soc. Mass Spectrom.* **20**, 601–610 (2009).

## Acknowledgements

We thank David J. Mangelsdorf (the University of Texas Southwestern Medical Center) for discussions related to SCA. Support is acknowledged from an endowed fellowship from the Frenchman's Creek Women for Cancer Research (S.S.); a fellowship from the Landenberger Foundation (D.P.M.); a NIH Pharmacological Sciences Training Grant (A.I.S.); a NIH Medical Scientist Training Program Grant (A.I.S.); a New Investigator Award 1KN-09 from the James and Esther King Biomedical Research Program, Florida Department of Health (D.J.K.); the National Institutes of Health (NIH) National Research Service Award (NRSA) DK097890 (T.S.H.) and Pathway to Independence Award DK103116 (T.S.H.); NIH grants DK101871 (D.J.K.), GM114420 (D.J.K.), GM063855 (M.R.), RR019077 (M.R.), RR027755 (M.R.), MH084512 (P.R.G.), GM084041 (P.R.G.), RR027270 (P.R.G.) and CA132022 (K.W.N.); and the State of Florida for institutional Scripps Florida start-up funds.

## Author contributions

E.M.-C., T.S.H., S.S., J.C.N., V.C., J.N., J.B.B. and A.I.S. expressed/purified protein and/or performed assays. D.J.K., E.M.-C., T.S.H. and M.R. performed NMR spectroscopy. J.B.B. and K.W.N. performed crystallography. M.J.C. and D.P.M. performed HDX mass spectrometry. T.M.K. synthesized compounds. D.J.K., P.R.G., and K.W.N. designed and

supervised the experiments. D.J.K. and K.W.N. wrote the manuscript with input from all the authors.

### Additional information

**Accession codes:** Atomic coordinates and structure factors have been deposited in the Protein Data Bank with accession code 4ZO1.

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** Kendall Nettles is a consultant for Genentech.

**Reprints and permission** information is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Kojetin, D. J. *et al.* Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. *Nat. Commun.* 6:8013 doi: 10.1038/ncomms9013 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>